Convatec Group PLC

M&A Activity • Mar 14, 2022

National Storage Mechanism | Additional information

RNS Number : 6368E

ConvaTec Group PLC

14 March 2022

14 March 2022

ConvaTec Group completes acquisition of Triad Life Sciences Inc

Further to the announcement of 28 January 2022, ConvaTec Group Plc (CTEC:LON) is pleased to announce that it has completed the acquisition of Triad Life Sciences Inc ('Triad').

The Triad team, current portfolio and product pipeline will now transition to ConvaTec's Advanced Wound Care (AWC) business and be known as ConvaTec Advanced Tissue Technologies.

***

Contacts

Analysts & Investors	Kate Postans, Vice President of Investor Relations & Corporate Communications	+44 (0) 7826 447807 ir@convatec.com
Media	Buchanan: Charles Ryland / Chris Lane	+44 (0)207 466 5000

About ConvaTec

ConvaTec is a FTSE 250 global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. We have more than 10,000 colleagues and sell our products and services in over 100 countries. Our vision is Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Group revenues in 2021 were over $2 billion. To learn more about ConvaTec, please visit http://www.convatecgroup.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQGPUQWWUPPUQC